Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Change in Accured Expenses (2023 - 2025)

Metagenomi (MGX) has disclosed Change in Accured Expenses for 3 consecutive years, with -$3.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 902.83% to -$3.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.6 million, a 83.87% decrease, with the full-year FY2025 number at -$1.6 million, down 83.87% from a year prior.
  • Change in Accured Expenses was -$3.2 million for Q4 2025 at Metagenomi, down from $4.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $4.0 million in Q3 2025 to a low of -$3.2 million in Q4 2025.
  • A 3-year average of -$75500.0 and a median of -$73000.0 in 2024 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 539.67% in 2025; the steepest drop was 902.83% in 2025.
  • Metagenomi's Change in Accured Expenses stood at $902000.0 in 2023, then plummeted by 135.25% to -$318000.0 in 2024, then tumbled by 902.83% to -$3.2 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's Change in Accured Expenses are -$3.2 million (Q4 2025), $4.0 million (Q3 2025), and $172000.0 (Q2 2025).